Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis
暂无分享,去创建一个
C. Trautwein | T. Roskams | R. De vos | M. Dréano | H. Wasmuth | C. Liedtke | Y. Malato | N. Beraza | S. Vander Borght | N. Beraza | Y. Malato | S. Vander Borght | C. Liedtke | H. E. Wasmuth | M. Dreano | R. de Vos | T. Roskams | C. Trautwein
[1] K. Rajewsky,et al. Conditional disruption of IκB kinase 2 fails to prevent obesity-induced insulin resistance , 2004 .
[2] J. Horton,et al. Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.
[3] E. Brunt. Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.
[4] G. Gores,et al. O0040 FREE FATTY ACIDS PROMOTE HEPATIC LIPOTOXICITY BY STIMULATING TNF‐ALPHA EXPRESSION VIA A LYSOSOMAL PATHWAY , 2004, Journal of Pediatric Gastroenterology and Nutrition.
[5] G. Gores,et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway , 2004 .
[6] J. Maher. Alcoholic steatosis and steatohepatitis. , 2002, Seminars in gastrointestinal disease.
[7] J. Kench,et al. Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.
[8] T. Luedde,et al. Deletion of IKK 2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia / reperfusion injury , 2005 .
[9] Philippe Lefebvre,et al. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis , 2006 .
[10] B. Staels,et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. , 2006, The Journal of clinical investigation.
[11] Hartmut Jaeschke,et al. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. , 2003, American journal of physiology. Gastrointestinal and liver physiology.
[12] C. Day,et al. Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.
[13] A. Hevener,et al. IKK-β links inflammation to obesity-induced insulin resistance , 2005, Nature Medicine.
[14] K. Rajewsky,et al. Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. , 2004, The Journal of clinical investigation.
[15] B. Spiegelman,et al. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. , 1997, The Journal of clinical investigation.
[16] T. Awata,et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. , 2001, Metabolism: clinical and experimental.
[17] Youngkyu Park,et al. A Dominant Negative Peroxisome Proliferator-activated Receptor-γ Knock-in Mouse Exhibits Features of the Metabolic Syndrome* , 2005, Journal of Biological Chemistry.
[18] M. Papa,et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. , 1993, The Journal of biological chemistry.
[19] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.
[20] R. Daynes,et al. Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging* , 1998, The Journal of Biological Chemistry.
[21] T. Okumura,et al. Increased expression of PPARγ in high fat diet-induced liver steatosis in mice , 2005 .
[22] G. Gores,et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. , 2003, Journal of hepatology.
[23] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. , 2005, Nature medicine.
[24] Michael Karin,et al. Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.
[25] V. Imbert,et al. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells , 2003, Oncogene.
[26] T. Okanoue,et al. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. , 2004, Biochemical and biophysical research communications.
[27] H. Cortez‐Pinto,et al. Non-alcoholic steatohepatitis: from cell biology to clinical practice. , 2006, Journal of hepatology.
[28] S. Kihara,et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. , 2003, Gastroenterology.
[29] S. Kihara,et al. Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.
[30] Yuichi Harano,et al. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats , 2004 .
[31] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[32] T. Niki,et al. A selective novel low‐molecular‐weight inhibitor of IκB kinase‐β (IKK‐β) prevents pulmonary inflammation and shows broad anti‐inflammatory activity , 2005 .
[33] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[34] J. Tran van Nhieu,et al. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis , 2004, Hepatology.
[35] T. Awata,et al. The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells , 2001 .
[36] Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. , 2005, The Journal of clinical investigation.
[37] J. Peters,et al. Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.
[38] L. Tartaglia,et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.
[39] I. Leclercq,et al. Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice , 2003, Hepatology.
[40] J. Peters,et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). , 1998, The Journal of biological chemistry.
[41] L. Romics,et al. Diverse regulation of NF‐κB and peroxisome proliferator‐activated receptors in murine nonalcoholic fatty liver , 2004, Hepatology.
[42] G. Farrell,et al. Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.
[43] M. Desai,et al. Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.
[44] D. Pessayre,et al. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. , 2002, American journal of physiology. Gastrointestinal and liver physiology.
[45] G. Pacini,et al. Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease , 2005, Hepatology.
[46] A. Moser,et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.
[47] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.
[48] Jan Weber,et al. Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. , 2005, Biochemical pharmacology.
[49] G. Gores,et al. Apoptosis: The nexus of liver injury and fibrosis , 2004, Hepatology.
[50] G. Shulman,et al. On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .
[51] A. Hevener,et al. IKK-beta links inflammation to obesity-induced insulin resistance. , 2005, Nature medicine.
[52] T. Okumura,et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. , 2005, Biochemical and biophysical research communications.
[53] G. Shulman,et al. Prevention of fat-induced insulin resistance by salicylate. , 2001, The Journal of clinical investigation.
[54] G. Barish,et al. PPARs and the complex journey to obesity , 2004, Nature Medicine.